{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:14:07Z","timestamp":1783538047352,"version":"3.55.0"},"reference-count":59,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Factor VIII and IX inhibitors in congenital hemophilia A and B, respectively, neutralize the infused coagulation factor concentrate rendering them ineffective. Bypassing agents (BPAs) that circumvent the block imposed by the inhibitors are used for the prevention and management of bleeding. Activated prothrombin complex concentrate was the original BPA, recombinant activated factor VII was then introduced, and more recently nonfactor agents that target the procoagulant and anticoagulant systems have been developed and are in clinical use (e.g., emicizumab, a bispecific antibody for hemophilia A). Other BPAs are in clinical trials (e.g., fitusiran targets antithrombin, concizumab and marstacimab target tissue factor pathway inhibitor, and SerpinPC targets activated protein C). The BPAs have a varied effect on coagulation assays, and as more patients are exposed to these agents, it is important to be aware of the effects. Herein, we present an overview of the effect of BPAs on routine and specialized coagulation assays including thrombin generation and viscoelastic assays.<\/jats:p>","DOI":"10.1055\/s-0043-1768660","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T23:12:56Z","timestamp":1683328376000},"page":"651-660","source":"Crossref","is-referenced-by-count":8,"title":["The Use of Bypassing Treatment Strategies in Hemophilia and Their Effect on Laboratory Testing"],"prefix":"10.1055","volume":"49","author":[{"given":"Rajiv K.","family":"Pruthi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Comprehensive Hemophilia Center, Rochester, Minnesota"},{"name":"Division of Hematopathology, Department of Laboratory Medicine and Pathology, Special Coagulation Laboratory, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Laboratory Medicine and Pathology, Special Coagulation Laboratory, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I","article-title":"Occurrence of hemophilia in the United States","volume":"59","author":"J M Soucie","year":"1998","journal-title":"Am J Hematol"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2013.06.002","article-title":"Hemophilia A in the third millennium","volume":"27","author":"M Franchini","year":"2013","journal-title":"Blood Rev"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"A Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/asheducation-2014.1.364","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"2014","author":"C L Kempton","year":"2014","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"R Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13108","article-title":"Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors","volume":"23","author":"J N Mahlangu","year":"2017","journal-title":"Haemophilia"},{"issue":"03","key":"ref7","first-page":"e141","article-title":"Continuous infusion of recombinant porcine factor VIII for neurosurgical management of intracranial haemorrhage in a patient with severe haemophilia A with factor VIII inhibitor","volume":"26","author":"G J Ruan","year":"2020","journal-title":"Haemophilia"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"K J Pasi","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"ref9","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"A D Shapiro","year":"2019","journal-title":"Blood"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.18495","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results","volume":"200","author":"J Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1055\/s-0040-1716751","article-title":"Serpins, new therapeutic targets for hemophilia","volume":"121","author":"K Aymonnier","year":"2021","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"e12695","DOI":"10.1002\/rth2.12695","article-title":"Impact of novel hemophilia therapies around the world","volume":"6","author":"M C Ozelo","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1182\/blood-2012-08-378935","article-title":"Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives","volume":"121","author":"G Young","year":"2013","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-9560-13-1","article-title":"A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis","volume":"13","author":"M D Lanc\u00e9","year":"2015","journal-title":"Thromb J"},{"key":"ref15","first-page":"85","volume-title":"Hemostasis screening assays","author":"G Rodgers","year":"2007"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.13215","article-title":"A critical appraisal of one-stage and chromogenic assays of factor VIII activity","volume":"14","author":"F Peyvandi","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jth.15287","article-title":"Recommendations for the measurement of thrombin generation: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"19","author":"M Ninivaggi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/jth.15529","article-title":"Thrombin generation assays are versatile tools in blood coagulation analysis: a review of technical features, and applications from research to laboratory routine","volume":"19","author":"F Depasse","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/rth2.12048","article-title":"A review of commercially available thrombin generation assays","volume":"2","author":"J Kintigh","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s10439-013-0817-3","article-title":"High sensitivity micro-elastometry: applications in blood coagulopathy","volume":"41","author":"G Wu","year":"2013","journal-title":"Ann Biomed Eng"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/ajh.26285","article-title":"Viscoelastic hemostatic assays: update on technology and clinical applications","volume":"96","author":"D Faraoni","year":"2021","journal-title":"Am J Hematol"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1055\/s-0042-1758162","article-title":"Laboratory testing for the evaluation of phenotypic activated protein C resistance","volume":"48","author":"L Morimont","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ijlh.12219","article-title":"Laboratory testing issues for protein C, protein S, and antithrombin","volume":"36","author":"R A Marlar","year":"2014","journal-title":"Int J Lab Hematol"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/jth.13976","article-title":"Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH","volume":"16","author":"K MJ Devreese","year":"2018","journal-title":"J Thromb Haemost"},{"key":"ref25","volume-title":"FEIBA (Anti-Inhibitor Coagulant Complex):","year":"2020"},{"key":"ref26","year":"2014"},{"issue":"S 02","key":"ref27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2004.00934.x","article-title":"FEIBA: mode of action","volume":"10","author":"P L Turecek","year":"2004","journal-title":"Haemophilia"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/hae.12873","article-title":"Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(\u00ae) in prophylactic therapy","volume":"22","author":"K Varadi","year":"2016","journal-title":"Haemophilia"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1538-7836.2005.01683.x","article-title":"Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI","volume":"4","author":"T Livnat","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1046\/j.1538-7836.2003.00450.x","article-title":"Monitoring the bioavailability of FEIBA with a thrombin generation assay","volume":"1","author":"K V\u00e1radi","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000071637","article-title":"Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay","volume":"33","author":"P L Turecek","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/cc9311","article-title":"Clinical review: prothrombin complex concentrates \u2013 evaluation of safety and thrombogenicity","volume":"15","author":"B S\u00f8rensen","year":"2011","journal-title":"Crit Care"},{"issue":"08","key":"ref33","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1538-7836.2012.04793.x","article-title":"Mechanisms and monitoring of bypassing agent therapy","volume":"10","author":"M Hoffman","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1532\/LH96.04048","article-title":"Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX","volume":"11","author":"M Keeney","year":"2005","journal-title":"Lab Hematol"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0049-3848(89)90268-5","article-title":"Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor","volume":"56","author":"D S Telgt","year":"1989","journal-title":"Thromb Res"},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/003655201750422701","article-title":"Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices","volume":"36","author":"E Ejlersen","year":"2001","journal-title":"Scand J Gastroenterol"},{"issue":"07","key":"ref37","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/MBC.0000000000000137","article-title":"Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors","volume":"25","author":"X Qi","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1053\/j.seminhematol.2003.11.021","article-title":"Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis","volume":"41","author":"M Shima","year":"2004","journal-title":"Semin Hematol"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00001721-200206000-00006","article-title":"Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation","volume":"13","author":"H G Hendriks","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"07","key":"ref40","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/jth.12987","article-title":"Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry","volume":"13","author":"S Furukawa","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"15","key":"ref41","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s40265-019-01200-2","article-title":"Emicizumab: a review in haemophilia A","volume":"79","author":"H A Blair","year":"2019","journal-title":"Drugs"},{"issue":"23","key":"ref42","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"P J Lenting","year":"2017","journal-title":"Blood"},{"issue":"05","key":"ref43","doi-asserted-by":"crossref","first-page":"e12561","DOI":"10.1002\/rth2.12561","article-title":"The effect of emicizumab and bypassing agents in patients with hemophilia - an in vitro study","volume":"5","author":"N H Schultz","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"07","key":"ref44","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"J I Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1111\/ijlh.13114","article-title":"Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays","volume":"42","author":"J I Adamkewicz","year":"2020","journal-title":"Int J Lab Hematol"},{"issue":"05","key":"ref46","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12185-020-02959-x","article-title":"A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa\/X","volume":"112","author":"K Ogiwara","year":"2020","journal-title":"Int J Hematol"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/hae.14213","article-title":"Comparison of bypassing agents in patients on emicizumab using global hemostasis assays","volume":"27","author":"H Kizilocak","year":"2021","journal-title":"Haemophilia"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12185-019-02698-8","article-title":"Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis","volume":"110","author":"K Yada","year":"2019","journal-title":"Int J Hematol"},{"key":"ref49","first-page":"154","article-title":"Use of thromboelastography to monitor emicizumab in a patient with severe haemophilia A without inhibitor","volume":"4","author":"G LCF Tiscia","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"04","key":"ref50","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1111\/hae.14330","article-title":"Thromboelastometry detects enhancement of coagulation in blood by emicizumab via intrinsic pathway","volume":"27","author":"T Szanto","year":"2021","journal-title":"Haemophilia"},{"issue":"06","key":"ref51","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran - results of the phase 1 inhibitor cohort","volume":"19","author":"K J Pasi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"S 01","key":"ref53","first-page":"S7","article-title":"Tissue factor pathway inhibitor and the current concept of blood coagulation","volume":"6","author":"G J Broze Jr","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref54","volume-title":"In Vitro Effect of Concizumab on Protein C Activation and Antithrombin Activity [abstract]","author":"M Kjalke","year":"2020"},{"key":"ref55","volume-title":"Concizumab Does Not Affect Activated Partial Thromboplastin Time, Prothrombin Time or Factor VIII\/IX Activity Measured Using One-Stage Clotting or Chromogenic Substrate Assays [abstract]","author":"M Kjalke","year":"2020"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/hae.13627","article-title":"Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic\/pharmacodynamic modelling results of concizumab phase 1\/1b data","volume":"25","author":"H Eichler","year":"2019","journal-title":"Haemophilia"},{"issue":"05","key":"ref58","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.13260","article-title":"Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay","volume":"23","author":"E K Waters","year":"2017","journal-title":"Haemophilia"},{"issue":"07","key":"ref59","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/jth.15323","article-title":"Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: in vitro and ex vivo analyses","volume":"19","author":"M Kjalke","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/hae.13820","article-title":"Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas","volume":"25","author":"S Patel-Hett","year":"2019","journal-title":"Haemophilia"},{"issue":"01","key":"ref61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2016-05-718635","article-title":"Design and characterization of an APC-specific serpin for the treatment of hemophilia","volume":"129","author":"S G Polderdijk","year":"2017","journal-title":"Blood"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1768660.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T23:38:30Z","timestamp":1691797110000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1768660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":59,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2023,8,11]]},"published-print":{"date-parts":[[2023,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1768660","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]}}}